Cannabis Europa returns to Paris on February 19, 2026

The February 19, 2026, Cannabis Europa Paris 2026 will be back in the French capital, after a first edition in 2019.

Bringing together political decision-makers, healthcare professionals, industry leaders and investors at the’Hotel de l'Industrie, the event is positioned as a key forum for examining France's potential transition from long-standing experimentation to a national framework for the medical marijuana.

Organized in partnership with’UIVEC, representing over sixty agricultural, pharmaceutical and economic players along the hemp extract value chain, the conference comes at a pivotal time.

After several years of experimentation and a generalization postponed on numerous occasions, Today, France leaves patients and companies in the dark. And yet.., the framework she has prepared could influence cannabis policy far beyond its borders.

Cannabis Europa is organizing a one-day conference on the theme of medical cannabis and foreign models.

From pilot project to national policy

The morning sessions will be largely devoted to public policy. The French pilot program, launched under strict conditions, has generated a substantial body of concrete data on results for patients, prescribing practices and operational challenges. Policy-makers and experts will assess which elements of this pilot project should become permanent features of a national roll-out.

Discussions will also focus on how France can reconcile its traditionally cautious healthcare governance with growing patient demand and increasing numbers of European precedents.

The opening speech, entitled« From pilot project to policy in practice », will set the tone by presenting France's transition as a moment with continental implications, particularly in terms of regulatory credibility and pharmaceutical investment.

Building a French supply chain for medical cannabis

One of the key economic issues addressed at the event is that of national production. Round tables dedicated to cannabis «Made in France» will examine how the country can capitalize on its agricultural expertise while complying with pharmaceutical standards. EU-GMP. The challenge is not only to guarantee supply, but to do so in a way that reflects France's emphasis on quality, traceability and public health surveillance.

Industry players will also analyze the role of stakeholders in hemp extracts, and how existing know-how could be adapted to a regulated medical market.

The reimbursement will be another major theme from Cannabis Europa Paris 2026. Defining who pays, for what indications and under what conditions remains one of the most sensitive aspects of the future French system. Panels will explore evidence thresholds, pricing models and eligibility criteria, highlighting the tension between political ambition and economic viability.

Clinical pathways and international comparisons

The afternoon will be devoted to clinical practice. Speakers will examine how cannabis-based medicines could be integrated into existing care pathways in France, from prescription by a specialist to dispensing in pharmacies. Particular attention will be paid to product formats and therapeutic diversity, with France seeking to strike a balance between pharmaceutical discipline and meaningful choice for patients.

International case studies shed further light. Visit clinical data collected in Canada over the past ten years are a benchmark for long-term follow-up and pharmacist involvement, while the Luxembourg and the Switzerland are presented as pragmatic, pharmacy-based models that France could adapt more quickly.

More than a national conference, Cannabis Europa Paris 2026 reflects a wider European debate. While regulatory frameworks are evolving unevenly across the continent, France's decisions in 2026 could serve as a signal for other countries considering their own path on medical cannabis.

More information on the Cannabis Europa.